Yihong Ling

2.1k total citations
58 papers, 1.2k citations indexed

About

Yihong Ling is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Yihong Ling has authored 58 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 21 papers in Surgery and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Yihong Ling's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer, Lipids, and Metabolism (8 papers) and Esophageal Cancer Research and Treatment (7 papers). Yihong Ling is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer, Lipids, and Metabolism (8 papers) and Esophageal Cancer Research and Treatment (7 papers). Yihong Ling collaborates with scholars based in China, United States and Hong Kong. Yihong Ling's co-authors include Shihong Wen, Rong Guo, Shaohua Li, Wei Wei, Jiantong Shen, Lianghe Lu, Minshan Chen, Jing Wen, Jie Mei and Lie Zheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Yihong Ling

55 papers receiving 1.2k citations

Peers

Countries citing papers authored by Yihong Ling

Since Specialization

Citations

This map shows the geographic impact of Yihong Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yihong Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yihong Ling more than expected).

Fields of papers citing papers by Yihong Ling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yihong Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yihong Ling. The network helps show where Yihong Ling may publish in the future.

Co-authorship network of co-authors of Yihong Ling

This figure shows the co-authorship network connecting the top 25 collaborators of Yihong Ling. A scholar is included among the top collaborators of Yihong Ling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yihong Ling. Yihong Ling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive Multiomics Characterization of Perineural Invasion in Cervical Cancer Reveals Diagnostic Markers, Molecular Drivers, and Therapeutic Strategies 2025 ·Cancer Research ·Ting Wan, Ting Deng, Xinxin Peng, Guangyao Cai, He Huang, Yihong Ling, (unknown), (unknown), (unknown), Haonan Li, Yining Zhao, Han Liang, Jihong Liu	0
2	Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis 2024 ·Journal of Hepatocellular Carcinoma ·(unknown), Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wen‐Ping Lin, Wei Wei, Rong Guo	4
3	Nomogram for predicting pathological response to neoadjuvant treatment in patients with locally advanced gastric cancer: Data from a phase III clinical trial 2024 ·Cancer Medicine ·S. Han, (unknown), Yihong Ling, (unknown), (unknown), (unknown), Zhiwei Zhou, Yu‐Jing Zhang	3
4	Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial 2024 ·EClinicalMedicine ·(unknown), Yihong Ling, Baoqing Chen, Yujia Zhu, Yonghong Hu, Mengzhong Liu, (unknown), Li Zhang, (unknown), Shiliang Liu, Qiaoqiao Li, Mian Xi	0
5	Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma 2023 ·Journal of Cancer Research and Clinical Oncology ·Wenping Lin, Lianghe Lu, Rongliang Zheng, (unknown), Shaohua Li, Yihong Ling, Wei Wei, Rong Guo	6
6	Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients 2023 ·European Journal of Cancer ·Jiehai Yu, Binyi Xiao, Jinghua Tang, Dandan Li, Fang Wang, Ya Ding, Kai Han, Ling-Heng Kong, Yihong Ling, Wei-Jian Mei, (unknown), (unknown), Wan-jun Yang, Zhizhong Pan, Xiaoshi Zhang, Jiang Wu, Peirong Ding	11
7	The apolipoprotein B and apolipoprotein A-I Ratio serves as a strong prognostic factor for the overall survival of patients with colorectal cancer 2023 ·Frontiers in Oncology ·Yangxun Pan, (unknown), Yihong Ling, (unknown), Chenwei Wang, Gong Chen, Desen Wan, Minshan Chen, Dandan Hu	6
8	Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma 2022 ·EBioMedicine ·Jing Wen, (unknown), Yi Hu, Mian Xi, (unknown), (unknown), Kongjia Luo, Yihong Ling, Renchun Lai, Xiuying Xie, Xiaodan Lin, Ting Lin, Jian‐Zhang Chen, Qianwen Liu, Jianhua Fu, Hong Yang	20
9	Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer 2021 ·Journal for ImmunoTherapy of Cancer ·Qiaoqi Sui, Dingxin Liu, Jiang Wu, Jinghua Tang, Ling-Heng Kong, Kai Han, (unknown), Yuan Li, Qingjian Ou, Binyi Xiao, Guochen Liu, Yihong Ling, Jiewei Chen, Zexian Liu, Zhixiang Zuo, Zhizhong Pan, Penghui Zhou, Jian Zheng, Peirong Ding	43
10	The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer 2021 ·OncoImmunology ·Xiaoli Wei, Qianwen Liu, Furong Liu, Shasha Yuan, Xiaofen Li, Jianing Li, Anli Yang, Yihong Ling	17
11	A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion 2021 ·Hepatology International ·Lianghe Lu, Wei Wei, (unknown), Shaohua Li, Chong Zhong, Jiahong Wang, (unknown), Yongfa Zhang, Minshan Chen, Yihong Ling, Rong Guo	27
12	Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice 2021 ·HepatoBiliary Surgery and Nutrition ·Shaohua Li, Jie Mei, Qiaoxuan Wang, Feng Shi, Hongyan Liu, Ming Zhao, Lianghe Lu, Yihong Ling, Zhixing Guo, Yabing Guo, (unknown), Ming Shi, Wan Yee Lau, Wei Wei, Rong Guo	15
13	Immune‐related adverse events predict responses to PD‐1 blockade immunotherapy in hepatocellular carcinoma 2021 ·International Journal of Cancer ·Lianghe Lu, (unknown), Wei Wei, Yihong Ling, Peng Li, Shaohua Li, Yan Wang, Dan Xie, Rong Guo, Muyan Cai	16
14	A better prognostic stratification for the 8th edition of the AJCC staging system of gastric cancer by incorporating pT4aN0M0 into stage IIIA 2019 ·Surgical Oncology ·Yongming Chen, Guanrong Zhang, (unknown), Chunyu Huang, Yihong Ling, Yuanfang Li, Zhiwei Zhou	1
15	Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases 2019 ·Journal of Cancer ·Shaohua Li, Qiaoxuan Wang, Jie Mei, Jianwei Wang, Xiao-Ping Zhong, Yihong Ling, Zhixing Guo, (unknown), Wei Wei, Rong Guo	5
16	Targeting intestinal epithelial cell–programmed necrosis alleviates tissue injury after intestinal ischemia/reperfusion in rats 2018 ·Journal of Surgical Research ·Xiang Li, Yihong Ling, (unknown), Jiantong Shen, (unknown), Weifeng Liu, (unknown), Shihong Wen	26
17	Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer 2018 ·Cancer Management and Research ·Xuan Xie, Kongjia Luo, Yi Li, Yihong Ling, Shuishen Zhang, Xiuying Xie, Jing Wen	7
18	miR-424 coordinates multilayered regulation of cell cycle progression to promote esophageal squamous cell carcinoma cell proliferation 2018 ·EBioMedicine ·Jing Wen, Yi Hu, Qianwen Liu, Yihong Ling, Shuishen Zhang, Kongjia Luo, Xiuying Xie, Jianhua Fu, Hong Yang	38
19	[Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification]. 2014 ·PubMed ·Yanfen Feng, Jia Fu, Shumei Yan, Yihong Ling, Yili Huang, Muyan Cai, Hui‐Lan Rao	2
20	Ischemic postconditioning during reperfusion attenuates oxidative stress and intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion via aldose reductase 2012 ·Surgery ·Shihong Wen, Yihong Ling, Yi Li, Li Cai, Jiaxin Liu, Yunsheng Li, Xi Yao, (unknown), Ke‐Xuan Liu	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact